Integra Holdings – Investing in Academic Innovation

THE RIGHT
TO
CHOOSE THE GOLDEN
OPPORTUNITIES

BRINGING HEBREW
UNIVERCITY
LIFE SCIENCES
BREAKTHROUGHS
TO MARKET

THE
KNOW-HOW
TO BUILD
COMMERCIAL
SUCCESS

BRINGING HEBREW
UNIVERCITY
LIFE SCIENCES
BREAKTHROUGHS
TO MARKET

THE SCIENTIFIC
INNOVATIONS
TO MAKE
THE COMPANY
GROW

BRINGING HEBREW
UNIVERCITY
LIFE SCIENCES
BREAKTHROUGHS
TO MARKET

Our expert team is the first to examine and evaluate the Hebrew University’s biomedical breakthroughs. We then capitalize decades of experience – transforming the inventions into pioneering companies.

Our golden eggs

Ayana Pharma
A late stage company with a unique lipid-based cytotoxic agent cytotoxic agent in preparations for review by FDA for marketing authorization.

Atox Bio
A Phase III company that develops host-directed therapeutics to control life-threatening infections.

Lipomedix
A Phase Ib company that develops a novel liposomal prodrug of a cytotoxic agent for cancer therapy.

Neoprol
A preclinical company with a unique formulation of the widely used anesthetic agent, Propofol, that provides a solution to the main drawback of the commercial product Diprivan, bacterial contamination.

Lipocure
A preclinical stage company that develops novel liposomal formulations of known drugs for post-surgical pain.

OPhRx
A preclinical company developing novel topical non-invasive formulations of approved drugs to ocular uses, targeting major disease states and clinical needs.

Hil Applied Medical Ltd
A medical device company with breakthrough laser-based technology that reduces the size, complexity and cost of proton accelerators, marking a significant leap in radiation therapy.

Splisense
A preclinical company developing novel antisense oligonucleotides for specific genetic mutations in Cytic Fibrosis, a disease with great unmet clinical needs.

Nectin Therapeutics
A preclinical company developing novel monoclonal antibodies targeting novel immune-checkpoint mechanisms in oncology, focusing on the Nectin family of receptors.

BacoCure
This company is developing a novel bacterial product for local therapy (intravesicular) of non-muscle invasive bladder cancer (NMIBC) patients.

HighRAD
HighRAD provides the first Intelligent Computer Assessment Support (iCASTM) system that delivers a trusted, automatic and enriched view of multi-organ imaging longitudinal data to improve healthcare outcomes and help stop disease progression.

The best innovations in Israeli biotech

BRINGING
ACADEMIC EXCELLENCE

TO MARKET